New drug trial aims to slow advanced prostate cancer growth
NCT ID NCT02905318
Summary
This study is testing whether a drug called palbociclib can help control advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It involves 19 men whose cancer has progressed despite previous therapies. Researchers will monitor how the cancer responds, track side effects, and look for biological markers that might predict which patients benefit most.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
-
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 3E4, Canada
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
London Regional Cancer Program
London, Ontario, N6A 5W9, Canada
-
Odette Cancer Centre
Toronto, Ontario, M4N 3M5, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, B3H 1V7, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.